Kardiovaskuläre Studien-Endpunkte bei Typ-2-Diabetes und die Sulfonylharnstoff-Kontroverse: Rationale für die aktiv kontrollierte CAROLINA®-Studie

B. Gallwitz; S. Thiemann; H. J. Wörle; N. Marx

doi:10.1055/s-0035-1553589

Diabetologie und Stoffwechsel, Table of Contents

Diabetologie und Stoffwechsel 2015; 10(04): 189-196
DOI: 10.1055/s-0035-1553589

Übersicht

Kardiovaskuläre Studien-Endpunkte bei Typ-2-Diabetes und die Sulfonylharnstoff-Kontroverse: Rationale für die aktiv kontrollierte CAROLINA^®-Studie

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA^® trial

B. Gallwitz

¹Medizinische Klinik IV, Universitätsklinikum Tübingen, Tübingen, Germany

,

S. Thiemann

²Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany

,

H. J. Wörle

²Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany

,

N. Marx

³Medizinische Klinik I, Universitätsklinikum Aachen, Aachen, Germany

› Author Affiliations

Abstract

Zusammenfassung

Sulfonylharnstoffe (SH) sind häufig verwendete glukosesenkende Therapeutika für Patienten mit Typ-2-Diabetes-mellitus (T2DM). In Bezug auf kardiovaskuläre Effekte dieser Substanzen zeigen Beobachtungs- und Registerstudien divergierende und zum Teil widersprüchliche Ergebnisse. Die vorliegende Arbeit analysierte den Einfluss von SH auf kardiovaskuläre Endpunkte in längerfristigen randomisierten Studien mit aktivem Vergleichsarm. Die Auswertung von insgesamt 18 Studien zeigte keinen Anhalt für eine erhöhte Inzidenz kardiovaskulärer Ereignisse unter einer SH-Therapie. Die verfügbaren Daten sind jedoch begrenzt und darüber hinaus herrscht ein Mangel an prospektiv geplanten, wirkstoffkontrollierten Studien mit hinreichender Teststärke für eine vergleichende Bewertung kardiovaskulärer Effekte. Da SH weiterhin als Zweitlinienmedikamente in Kombination mit Metformin und gegebenenfalls als Erstlinientherapie bei Typ-2-Diabetes empfohlen werden, sind konkrete kardiovaskuläre Sicherheitsdaten aus einer prospektiven, randomisierten, kontrollierten Studie dringend benötigt. Die CAROLINA^®-Studie ist bis heute die größte Studie für kardiovaskuläre Endpunkte, die einen SH und einen Dipeptidyl-Peptidase-4-Inhibitor (DPP-4) direkt vergleicht. Aufgrund ihres Designs und ihrer Teststärke kann CAROLINA^® im Direktvergleich einen detailierten Einblick in die kardiovaskuläre Sicherheit dieser Wirkstoffe geben.

Abstract

Sulphonylureas (SUs) are antidiabetic agents widely used in patients with Type 2 Diabetes Mellitus (T2DM). Observational retrospective studies have raised concerns regarding the cardiovascular (CV) safety of this class of drugs, and data from observational and registry studies are conflicting. To address the SU controversy, this review looked at longer-term RCTs, where SUs were compared in a head-to-head fashion with active comparators. An analysis of 18 studies did not find any increase in the incidence of CV events with SU therapy. However, the available data are limited and most importantly, there is a lack of prospective, adequately powered, formal head-to-head CV outcome trials. Since SUs are still being used as second-line therapy in combination with metformin and in some cases as first-line treatment of T2DM, there is a definite need for CV safety data from a prospective RCT. The CAROLINA^® study is currently the largest CV outcome study with a direct comparison of an SU and a dipeptidyl peptidase-4 inhibitor (DPP-4). Based on the study design and statistical power of CAROLINA^®, its results will provide a unique perspective regarding CV outcomes of these 2 commonly used agents.

Schlüsselwörter

Typ-2-Diabetes - kardiovaskuläre Erkrankung - orale glukosesenkende Wirkstoffe - Sulfonylharnstoff - Dipeptidyl-Peptidase-4-Inhibitor

Keywords

type 2 diabetes - cardiovascular disease - oral antidiabetic agents - sulphonylurea - dipeptidyl peptidase-4 inhibitor

Full Text

References

Literatur
1 Giugliano D, Standl E, Vilsboll T et al. Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?. Acta Diabetol 2009; 46: 173-181
2 Ryden L, Grant PJ, Anker SD et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34: 3035-3087
3 US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry. Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf Letzter Zugriff am 29.04.2015
4 Skyler JS, Bergenstal R, Bonow RO et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009; 53: 298-304
5 Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17-30
6 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379
7 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
8 Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589
9 Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559
10 Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
11 Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139
12 Moritz T, Duckworth W, Abraira C. Veterans Affairs diabetes trial – corrections. N Engl J Med 2009; 361: 1024-1025
13 Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-2298
14 UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991; 34: 877-890
15 Meinert CL, Knatterud GL, Prout TE et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19: 789-830
16 Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 1972; 21: 976-979
17 Selvin E, Bolen S, Yeh HC et al. Cardiovascular outcomes in trials o. Arch Intern Med 2008; 168: 2070-2080
18 Evans JM, Ogston SA, Emslie-Smith A et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49: 930-936
19 Johnson JA, Majumdar SR, Simpson SH et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-2248
20 Rao AD, Kuhadiya N, Reynolds K et al. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 2008; 31: 1672-1678
21 Tzoulaki I, Molokhia M, Curcin V et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009; 339: b4731
22 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865
23 European Medicines Agency. European Medicines Agency 2011 priorities for drug safety research. Anti diabetic drugs: Cardio / cerebrovascular adverse effect and pancreatitis / pancreatic cancer. EMA/425259/2010 http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/07/WC500094264.pdf Letzter Zugriff am 29.04.2015
24 Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33: 187-215
25 Johansen OE, Neubacher D, von Eynatten M et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012; 11: 3
26 Iqbal N, Parker A, Frederich R et al. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol 2014; 13: 33
27 Williams-Herman D, Engel SS, Round E et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10, 246 patients with type 2 diabetes. BMC Endocr Disord 2010; 10: 7
28 Schweizer A, Dejager S, Foley JE et al. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vasc Health Risk Manag 2010; 7: 49-57
29 White WB, Pratley R, Fleck P et al. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15: 668-673
30 Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326
31 Green JB, Bethel MA, Paul SK et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J 2013; 166: 983-989
32 Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012; 380: 475-483
33 Balakumar P, Dhanaraj SA. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials. Cell Signal 2013; 25: 1799-1803
34 Kröller-Schön S, Knorr M, Hausding M et al. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res 2012; 96: 140-149
35 Hocher B, Sharkovska Y, Mark M et al. The novel DPP-4 inhibitors linagliptin and BI14361 reduce infarct size after myocardial ischemia / reperfusion in rats. Int J Cardiol 2013; 167: 87-93
36 Klamann A, Sarfert P, Launhardt V et al. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J 2000; 21: 220-229
37 Zeller M, Danchin N, Simon D et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 2010; 95: 4993-5002
38 Ye Y, Perez-Polo JR, Aguilar D et al. The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol 2011; 106: 925-952
39 Krall RL. Cardiovascular safety of rosiglitazone. Lancet 2007; 369: 1995-1996
40 Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443
41 Mazzone T, Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 2572-2581
42 Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-1573
43 Gerstein HC, Ratner RE, Cannon CP et al. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation 2010; 121: 1176-1187
44 Matthews DR, Dejager S, Ahren B et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010; 12: 780-789
45 Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm Metab Res 2009; 41: 905-909
46 Seck T, Nauck M, Sheng D et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010; 64: 562-576
47 Chacra AR, Tan GH, Ravichandran S et al. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res 2011; 8: 150-159
48 Garber A, Henry RR, Ratner R et al. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 348-356
49 Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135
50 Frye RL, August P, Brooks MM et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. BARI 2D Study Group. N Engl J Med 2009; 360: 2503-2515
51 Abraira C, Duckworth WC, Moritz T. Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab 2009; 11: 150-156
52 Calles-Escandon J, Lovato LC, Simons-Morton DG et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33: 721-727